Australia: The ALRC Delivers Its Report Into Gene Patenting And Human Health

Last Updated: 15 March 2005

By Amanda Turnill, partner, Clayton Utz and Jodi Ainsworth, graduate at law, Clayton Utz.

Key Point

  • The Australian Law Reform Commission has completed a major examination of gene patenting to ensure that Australia's intellectual property laws can deal with the rapid advances being made in genetic research.

After an 18 month inquiry, the Australian Law Reform Commission ("ALRC") has recently released its report into gene patenting and human health, Genes and Ingenuity: Gene Patenting and Human Health ("the Report"). This Report, which makes 50 recommendations regarding the patenting of genes, was tabled in Parliament on 31 August 2004. Its release follows the ALRC's report into genetic privacy and discrimination, which revealed a need to review gene patenting laws. It also follows the public debate over Myriad Genetics Inc's patenting of genes which can identify a predisposition to breast and ovarian cancer, the BRCA genes.

The Report considers the impact of patent laws and practices regarding genes and genetic technologies on:

  • Research, and its commercialisation;
  • The Australian biotechnology sector; and
  • Cost-effective healthcare in Australia.

This article considers some of the main recommendations of the Report.

1. Genetic materials and technologies should remain patentable

IP Australia has granted patent protection under the Patents Act 1990 (Cth) ("Patents Act") for numerous inventions involving genetic materials and technologies including:

  • Synthetic genetic sequences;
  • Mutants and fragments of genetic sequences;
  • Isolated or recombinant DNA coding for a sequence of a gene;
  • Proteins expressed by a gene;
  • Host cells, higher plants or animals carrying a gene; and
  • Recombinant DNA methods, such as polymerase chain reaction and novel expression systems.

These so-called gene patents have prompted concerns about the patentability requirements and also about the way in which these gene patents are exploited. Some of the specific concerns include:

  • Ethical issues;
  • The identification of a gene is a ‘discovery’, not a patentable ‘invention’;
  • Genetic material is not novel and should not be patentable; and
  • The identification of genetic material does not involve an inventive step.

After considering these concerns, the ALRC recommended that the Commonwealth should not amend the Patents Act to exclude the patenting of genetic materials. The reasons cited by the ALRC for this recommendation include: the long history of patenting such inventions; the harm the amendment would cause the Australian biotechnology industry; and the conflict it would generate with Australia's international obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights 1994. Any social and ethical concerns should be dealt with through regulation of the use or exploitation of these patents.

The ALRC also concluded that gene patents should be assessed using the same criteria as other inventions. However, the ALRC's investigations revealed a generic problem in the way 'usefulness' is assessed under the Patents Act. Currently there is confusion as to the extent to which an invention claimed in a patent application must be useful and how this requirement is imposed. To address this confusion, the ALRC recommended that ‘usefulness’ be included as a requirement in the examination for a standard patent and that an invention should only satisfy this requirement if the patent application discloses a specific, substantial and credible use.

2. There should be a statutory exemption in patent law for experimentation

There is no express exemption from infringement liability in the Patents Act for experimental or research use of patented inventions. There is concern that this may have a 'chilling effect' on research.

To deal with this concern, the ALRC recommended that an experimental use exemption be inserted into the Patents Act. The Report also contains a recommendation that bodies which fund research, for example the Australian Research Council ("ARC") and the National Health and Medical Research Council ("NH&MRC"), place conditions on their funding to encourage dissemination of the resulting research.

3. The effect of gene patents on the healthcare system should be monitored

Gene patents are relevant to the provision of healthcare, in particular:

  • Medical genetic testing; and
  • Novel therapies, including gene therapy, the production of therapeutic proteins, and the use of stem cells.

There is a concern that gene patents may make the provision of these kinds of healthcare more expensive. However, the ALRC found that, to date, there is no evidence to suggest this. The ALRC recommended that the impact of gene patents on cost-effective healthcare be monitored, and if a gene patent is adversely affecting healthcare, health departments should examine legal options to open up access to the invention. These options may include challenging the patent or reporting anti-competitive conduct to the Australian Competition and Consumer Commission ("ACCC").

4. Education within the biotechnology industry regarding licensing should be increased

The Australian biotechnology industry heavily relies on patent licensing. There is potential for licences to be granted in a restrictive manner, but the ALRC concluded that such restrictive practices are not common in Australia. However, the ALRC did observe that there is a lack of commercial experience regarding licensing gene patents. To address this, the ALRC recommended that education programs regarding such licensing be enhanced. Also, Ausbiotech Ltd (the peak biotechnology industry body) should develop model licence agreements and consider whether other iniatives are necessary.

5. Access to gene patents should be enhanced by Crown use provisions and compulsory licences

The Patents Act contains Crown use provisions which allow the Commonwealth or States to exploit a patented invention without infringment, or to authorise another person to do so. There are also provisions which enable the Commonwealth compulsorily to acquire the rights in a patented invention. The ALRC recommended that these provisions should be used in specific cases where gene patents are adversely affecting research or healthcare.

Compulsory licences may also be granted to enable access to a gene patent which is hindering research or healthcare. These licences are authorisations to exploit a patented invention where the 'reasonable requirements of the public' with respect to the patent have not been met, and the patent holder fails to explain why they have not exploited the patent. Compulsory licences are currently seldom used. The ALRC has propsed that a competition-based test be introduced into this provision to address those circumstances in which there is a public interest in enhanced competition in a market.

6. Copyright law should be amended

Scientists could potentially be able to protect the written representations of gene and protein sequences, and databases containing gene sequences, with copyright. Despite the fact that there are no problems currently, in the future copyright could hinder access or use of genetic information.

To address this concern, the ALRC recommended the 'fair dealing' exception for research and study in the Copyright Act 1968 (Cth) ("Copyright Act") be amended to ensure that research with a commercial purpose or objective can fall within this exception. The Copyright Act should be further amended to provide, for copyright in relation to databases, that the exception covering fair dealing for the purpose of research or study cannot be excluded or modified by contract.


The ALRC Report provides a detailed examination of the effects of gene patenting on research, the biotechnology industry and healthcare. This report does not propose any radical law reform. However, implementation of the Report's 50 recommendations has the potential to involve many different bodies, including Ausbiotech Ltd, the ACCC, the Australian Government, health departments (Commonwealth, state and territory), IP Australia, the ARC, the NH&MRC, research organisations and universities.

At the time of writing this article, the impact of the Report is yet to be seen. We will await with interest any announcements the Government will make regarding implementing of the ALRC's recommendations in this area.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.